Business Standard

Sun Pharma gains ahead of Q2 results

The company may report 29% y-o-y growth in its consolidated net profit at Rs 772 crore in Q2.

Related News

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

The stock opened at Rs 700 and hit a high of Rs 714 on the NSE. A combined 684,427 shares have changed hands on the counter so far against an average 609,000 shares that were traded daily in past ten trading days.

According to an average analyst estimates, may report 29% year-on-year growth in its consolidated net profit at Rs 772 crore in the September 2012 quarter. The company had reported profit of Rs 598 crore in previous year quarter.

“Sun Pharma is likely to report strong revenue growth at 50% led by 18% growth in domestic formulations, 49% growth in Taro US revenues and niche launches in US viz. Lipodex and Stalevo. Operating margins are likely to expand by over 600 bps to 40%,” according to analyst at Emkay Global Financial Services.

Read more on:   
|
|

Read More

BSE launches carbon index

Premier bourse BSE, in collaboration with the UK government, today launched BSE Carbonex, the first-of-its-kind index in India or any emerging market ...

Quick Links

 

Market News

Realty, infra shares extend rally on relaxation of FDI norms

Unitech, IVRCL Infra, HCC, GVK Power, NBCC,D B Realty, Patel Engg, Shriam EPC and Gayatri Projects are up 4-10%.

Sensex scales record high; Nifty within kissing distance

Unperturbed by end of US Fed's bond buying, equities post healthy gains

Higher open interest enthuses markets on expiry day

Rollover percentage in the Nifty was lower than three-month average, at 64%

Godrej Properties, Brigade, Mahindra Lifespace to gain from FDI in construction

Analysts perceive this development to be a positive for developers with existing joint development / investment arrangements with foreign ...

Realisation gains for ACC, Ambuja

While Ebitda margins improved in September quarter, led by higher prices, concerns on volume growth continue

Back to Top